Endothelial Dysfunction: a Novel Therapeutic TargetEndothelial Dysfunction in Human Disease
Abstract
The vascular endothelium plays a key role in the local regulation of vascular tone by the release of vasodilator substances (i.e. endothelium-derived relaxing factor (EDRF=nitric oxide, NO) and prostacyclin) and vasoconstrictor substances (i.e. thromboxane A2, free radicals, or endothelin). Using either agents like acetylcholine or changes in flow to stimulate the release of EDRF (NO), clinical studies have revealed the importance of EDRF in both basal and stimulated control of vascular tone in large epicardial coronary arteries and in the coronary microcirculation. The regulatory function of the endothelium is altered by cardiovascular risk factors or disorders such as hypercholesterolemia, chronic smoking, hypertension or chronic heart failure. Endothelial dysfunction appears to have detrimental functional consequences as well as adverse longterm effects, including vascular remodelling. Endothelial dysfunction is associated with impaired tissue perfusion particularly during stress and paradoxical vasoconstriction of large conduit vessels including the coronary arteries. These effects may cause or contribute to myocardial ischemia. Several mechanisms may be involved in the development of endothelial dysfunction, such as reduced synthesis and release of EDRF or enhanced inactivation of EDRF after its release from endothelial cells by radicals or oxidized low-density lipoprotein (LDL). Increased plasma levels of oxidized LDL have been noted in chronic smokers and are related to the extent endothelial dysfunction, raising the possibility that chronic smoking potentiates endothelial dysfunction by increasing circulating and tissue levels of oxidized LDL. In heart failure, cytokines and/or reduced flow (reflecting reduced shear stress) may be involved in the development of endothelial dysfunction and can be reversed by physical training. Other mechanisms include an activated renin-angiotensin system (i.e. postmyocardial infarction) with increased breakdown of bradykinin by enhanced angiotensin converting enzyme (ACE) activity. There is evidence that endogenous bradykinin is involved in coronary vasomotor control both in coronary conduit and resistance vessels. ACE inhibitors enhance endothelial function by a bradykinin-dependent mechanism and probably also by blunting the generation of superoxide anion. Endothelial dysfunction appears to be reversible by administering-arginine, the precursor of nitric oxide, lowering cholesterol levels, physical training, antioxidants such as vitamin C, or ACE inhibition.
References (0)
Cited by (446)
Intracellular peptides in SARS-CoV-2-infected patients
2023, iScienceIntracellular peptides (InPeps) generated by the orchestrated action of the proteasome and intracellular peptidases have biological and pharmacological significance. Here, human plasma relative concentration of specific InPeps was compared between 175 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and 45 SARS-CoV-2 non-infected patients; 2,466 unique peptides were identified, of which 67% were InPeps. The results revealed differences of a specific group of peptides in human plasma comparing non-infected individuals to patients infected by SARS-CoV-2, following the results of the semi-quantitative analyses by isotope-labeled electrospray mass spectrometry. The protein-protein interactions networks enriched pathways, drawn by genes encoding the proteins from which the peptides originated, revealed the presence of the coronavirus disease/COVID-19 network solely in the group of patients fatally infected by SARS-CoV-2. Thus, modulation of the relative plasma levels of specific InPeps could be employed as a predictive tool for disease outcome.
Onosma hispidum L. extract reverses hyperlipidemia, hypertension, and associated vascular dysfunction in rats
2023, Saudi Journal of Biological SciencesOnosma hispidum.L (O. hispidum) belongs to the family Boregineacea. A preliminary study and its medicinal use suggested its role in the management of hyperlipidemia. The present study aimed to assess the effect of methanolic root extract of O. hispidum in hyperlipidemia and associated vascular dysfunction. Oral administration of O. hispidum crude extract (Oh. Cr) to tyloxopol and high fat diet-induced hyperlipidemic Sprague-Dawley rats for 10 and 28 days significantly reduced total triglycerides and cholesterol (p < 0.001), compared to hyperlipidemic rats. Oh. Cr 250 mg/kg orally treated rats significantly (p < 0.001) reduced both the total body weight and atherogenic index in tylaxopol and HFD rats. In HMG-CoA assay, the inhibition of the enzyme was significant in Oh.Cr (250 mg/kg) treated group. Histopathological studies indicated that the group treated with Oh.Cr 250 mg/kg/day showed regular morphology of aortic intima, media and adventitia, and improved the endothelial damage. To investigate the vascular dysfunction, isolated rat aorta rings from all groups were pre-contracted with 1 µM phenylephrine (PE), and the effect of acetylcholine (Ach) was monitored. In the aorta isolated from Oh.Cr (50 mg/kg) treated group, Ach completely relaxed the PE-induced contraction with EC50 value of 0.05 µg/mL 0.015 (0.01–0.2) compared to the hyperlipidemic control group (<30% relaxation). In atorvastatin (10 mg/kg) treated rat aorta, Ach showed 50% relaxation. The Oh.Cr extract also reduced (105.92 ± 1.14 to 66.63 ± 0.85 mmHg) mean arterial pressure in hyperlipidemic hypertensive rats. These findings suggest that extract of O. hispidum is an effective remedy for hypercholesterolemia, and hypertriglyceridemia, which acts through inhibition of HMG-CoA and improving vascular dysfunction.
By examining pertinent studies, the current review investigated the relationship between ACE gene insertion/deletion (I/D) and the risk factors for CVD in order to establish the link between ACE gene polymorphism and CVD susceptibility.
Prior to May 2022, the most recent 20 years' worth of pertinent publications published on PubMed, Google Scholar, Research Gate, and Semantic Scholar were collected. The present study is conducted according to the PRISMA guidelines, 2020.
A total of 49 articles were retrieved from various sources for systematic review and identifying the ACE gene association with CVDs. This review discovered that the Asian population with the ACE gene D allele displayed a greater CVD's risk factor susceptibility in all of these models, which included the allelic model, homozygote model, dominant model, and regressive model. Additionally, in the Caucasian and Mixed populations, the ACE gene D allele was discovered to be strongly associated with CVD susceptibility.
All of the research included in this review found a link between the ACE gene insertion/deletion (I/D) polymorphism and CVD risk. The ACE gene D allele was related with a higher CVD susceptibility as compared to the ACE gene I allele.
Human C-peptide is a ligand of the elastin-receptor-complex and therewith central to human vascular remodelling and disease in metabolic syndrome
2022, Medical HypothesesThis hypothesis ties together various causal risk factors from our “Western-lifestyle” (elevated blood-glucose, smoking, processed red-meat-products, obesity, and inflammation) in a unifying perspective on the cause of human vascular disease in metabolic syndrome.
When, in response to enhanced blood-glucose levels, insulin is excreted, it is always excreted together with C-peptide. I identified an elastin-receptor-complex (ERC) binding amino-acid motif xGxxPG in C-peptide and pose that C-peptide’s earlier unknown receptor is this ERC. This receptor is involved in vascular remodelling, commonly activated by vascular-lesion-derived elastin-peptides with said motif xGxxPG. Systemic elastin-peptides may arise from smoking or from consuming elastin-rich processed red-meat-products, therewith interfering with vascular remodelling. Both excess elastin-peptides as well as excess C-peptide associate with core-manifestations of metabolic syndrome: insulin resistance, angiogenesis, and vascular remodelling. C-peptide fragments as well as elastin peptide-fragments with motif xGxxPG are angiogenic and blocked by antagonists of ERC. Many other bioactive peptides with an xGxxPG motif exist, a third example discussed here is galectin-3, elevated in obesity and inflammation, and again associated with insulin resistance, angiogenesis, and vascular remodelling in metabolic syndrome.
On the one side of this hypothesis, a lack of ERC-mediated vascular remodelling through a lack of C-peptide is central to microvascular disease in T1D. On the other side, excess ERC-activity through excess activation (by systemic C-peptide, elastin-peptide, galectin-3, or others), is centrally involved in metabolic syndrome and T2D, inducing insulin resistance with excess and maladaptive macrovascular remodelling. Systemic C-peptide is increased in a “Western-diet” lifestyle, systemic elastin peptides are increased after smoking and possibly after elastin-consumption, and systemic galectin-3 increases in chronic inflammation and obesity. As all these risk-factors associate with life-style mediated metabolic syndrome, this hypothesis poses one up-stream cause: excess activation of ERC stands central in causing metabolic syndrome.
Modification of vascular receptor pharmacology by cholesterol: From molecular determinants to impact on arterial function
2022, Cholesterol: From Chemistry and Biophysics to the ClinicData from epidemiological findings and clinical and preclinical studies all document a clear association between cardiovascular disease and cholesterol dyshomeostasis. Since pharmacological interventions play a significant role in the prevention and treatment of cardiovascular diseases, it becomes particularly relevant to examine the effects exerted by modifications of cholesterol levels in the body on the potency and/or efficacy of therapeutic agents commonly used to treat such diseases. The interaction between changes in cholesterol levels and cardiovascular drugs is often difficult to interpret since agents that modulate cholesterol levels in the body may exert so-called pleiotropic effects, which could modify cardiovascular drug action independently of changes in cholesterol levels. In this review, we first present phenomenological data summarizing the impact of cholesterol levels on the effect of main drugs used to treat cardiovascular disease where it remains unclear which specific pharmacodynamic process (es) participates in cholesterol–drug interaction, and even pharmacokinetic contributions cannot be ruled out. Next, we examine the modulation of vascular drug effects by cholesterol actions at the proteolipid membrane where the vascular drug receptor is embedded. Finally, we present a few examples where both cholesterol and vasoactive agents target the same membrane protein receptor, thus resulting in allosteric modulation of receptor function. This section includes data from our own group documenting cholesterol-alcohol regulation of Ca2+-activated K+ channels of the BK type, and the consequence of the interaction between these heterotrophic ligands of BK channels on cerebral artery diameter.
Endothelial dysfunction: basis for many local and systemic conditions
2022, The Vasculome: From Many, OneCardiovascular diseases are major contributors to global deaths and disability-adjusted life years, with hypertension as a significant risk factor for all cause death. The endothelium that lines the inner wall of the vasculature regulates essential hemostatic functions such as regulation of the vascular tone, circulation of blood cells, inflammation, and platelet activity. Endothelial dysfunction is an early biomarker for subclinical atherosclerosis and can also be considered as a predictor for future cardiovascular events. We review the mechanisms leading to endothelial dysfunction with focus on oxidative stress, the clinical techniques for its determination, the prognostic value of measurements of endothelial function, as well as therapeutic approaches to treat endothelial dysfunction. Since vascular oxidative stress and inflammation are major determinants of endothelial function, we also address current antioxidant and antiinflammatory therapies. In light of recent data that argue against the prognostic value of endothelial function in healthy human cohorts, we also discuss alternative diagnostic parameters such as vascular stiffness index and intima/media thickness ratio. We also suggest that investigation of vascular function, including that of the smooth muscle and even perivascular adipose tissue, may be appropriate parameters for clinical investigations.